Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 1, 2017. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a corporate governance notification regarding share capital and voting rights.
Material Changes
The filing does not report material changes in financial performance or operations compared to prior periods. It solely updates the record of issued share capital and treasury shares as of February 28, 2017.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures.
Important Facts for Investors
- Issued Share Capital: As of February 28, 2017, the Company had 5,370,130,274 ordinary shares of 25 pence each.
- Treasury Shares: 453,205,950 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,916,924,324.
- Regulatory Use: This figure serves as the denominator for shareholders calculating notification requirements under the Financial Conduct Authority's Disclosure and Transparency Rules.